Regenerative medicine is a new field that uses stem cell biology, biotechnology, and pharmaceutical sciences to fix or replace damaged tissues. Stem cell therapy, utilising embryonic, adult, and induced pluripotent stem cells (iPSCs), has demonstrated potential in the treatment of neurological, cardiovascular, musculoskeletal, and immune-related disorders. Pharmaceutical innovations, including small-molecule modulators, controlled drug delivery systems, nanotechnology, and gene-editing tools, have greatly increased the clinical use of stem cells by making them more viable, able to differentiate, and effective as treatments. However, there are still problems, such as large-scale production, standardisation, long-term safety, immunological rejection, and tumorigenic risks. It is more difficult to safely translate and use drugs in clinical settings around the world because different countries have different rules and morals. 3D bioprinting, nanomedicine, artificial intelligence, and the development of "off-the-shelf" stem cell products indicate that regenerative therapies will soon become more individualised and accessible to a broader population. Stem cell-based therapies have a lot of promise, but they need to be safe and work well before doctors can use them in their daily work. This means that issues with drugs, making them, and the law must be fixed.